Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer

Seasoned executive has more than 20 years of experience in the biotechnology and financial services industries.

NEW YORK, May 16, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.

Michael D. Becker, Chief Financial Officer, Relmada Therapeutics

Mr. Becker joined Relmada in 2014 as senior vice president of finance and corporate development. In his new role, he will be responsible for all corporate finance and accounting activities for the Company.

"We are pleased to expand Michael's role as we prepare for the continued growth and expansion of our operations at Relmada," said Sergio Traversa, CEO of Relmada Therapeutics. "Since joining the Company in 2014, Michael has consistently managed responsibilities of expanding scope and complexity. As we advance our pipeline through several critical upcoming milestones, sound financial planning and discipline will be even more important elements of our success. Michael's outstanding experience in both the biotechnology and financial services sectors together with his deep understanding of our business make him uniquely suited to lead our finance team moving forward."

Over the past two decades Mr. Becker served as both a C-level industry executive and a Wall Street securities analyst and registered financial advisor.  Prior to joining Relmada, he was founder and president of the consulting firm MDB Communications LLC since 2008.  In this position, he acted as a strategic advisor and senior consultant to many leaders in the life sciences industry including development of investor relations and public relations strategies to enhance client visibility and brand awareness.  Prior to that, Mr. Becker served as president, chief executive officer, and member of the board of directors for two publicly traded biotechnology companies, including commercial-stage Cytogen Corporation (acquired by EUSA Pharma).  He held positions of increasing responsibility prior to being appointed president and CEO of Cytogen in 2002, including vice president of business development, industry and investor relations and CEO of AxCell Biosciences, a subsidiary of Cytogen.  Prior to his industry career, Mr. Becker spent nine years in the financial services industry, including positions at Wayne Hummer Investments LLC, Kidder, Peabody & Co., Gruntal & Co., and Kemper Securities.  He completed coursework in political science at DePaul University and received an associate of science degree from the Art Institute of Pittsburgh.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (REL-1017), an  N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028),an  oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, please visit Relmada's website at:  

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.


Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 646-677-3857

Media Contact:
Lynn Granito
Berry & Company Public Relations
Tel: 212-253-8881


Relmada Therapeutics Corporate Logo


Photo -
Logo -

To view the original version on PR Newswire, visit:

SOURCE Relmada Therapeutics, Inc.